Add like
Add dislike
Add to saved papers

[Effects of DOT1L Inhibitor EPZ-5676 Combined with Chemotherapeutic Drugs on Prolifiration and Apoptosis of RS 4;11 Cells].

OBJECTIVE: To investigate the synergistic antiproliferative and inducing-apoptotic effect of EPZ-5676 combined with chemotherapeutic drugs on acute lymploblastic leukemia(ALL).

METHODS: The MLL rearragement positive (MLL-r+ ) ALL cell line RS4;11 was treated with EPZ-5676 alone and its combination with 5 kinds of chemotherapeutic drugs of ALL, the CCK-8 method was used to assay the inhibitory rate of leukemia cells treated with EPZ-5676 and chemotherapeutic drugs alone and their combination; the compusyn software was used to evaluate the relationthip between inhibitory rate (Fa) of combined drugs for leukemia cells and combination index (CI), and to determine the interaction of drugs; the flow cytometry with Annexin V-FITC/PI double staining was used to detect the apoptotic rate of RS4;11 treated EPZ-5676, GC, VCR, CTX, epirubicin and VP16 alone and combination of EPZ-5676 with them and to compare the inducing apoptotic effect of combined drugs.

RESULTS: The combination of EPZ-5672 with GC or VCR or VP16 showed synergistic antiproliferative effect; the combination of EPZ-5676 with TX or epirubicin displayed antogonistic effect. As compared with blank control group, 5, 10 and 25 µmol/L EPZ-5676 did not affected on apoptosis of RS4;11 cells, but 5 µmol/L EPZ-5676 combined with VCR of GC possessed synergistically inducing apoptotic effect (56.87% vs 12.93%)(P<0.01), (8.86% vs 5.28%)(P<0.05).

CONCLUSION: The EPZ-5676 combined with GC or VCR or VP16 possesses synergistic antiproliferative effect on RS4;11 cells, the effect of EPZ-5676 alone on apoptosis of RS4;11 cells is no significant, but the combination of low concentration EPZ-5676 with VCR or GC displays synergistically inducing apoptotic effect.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app